Lung Cancer Chemotherapy-Induced Myelosuppression: Clinical Analysis Of Risk Factors

Objective:to explore the related dangerous factors after lung cancer chemotherapy Myelosuppression, based on which, to promote the research deeply, so that could be forward-looking assessment of lung cancer patients Chemotherapy-InducedⅢdegrees or higher risk of bone marrow suppression; the same time, the clinical development of chemotherapy regimens have a certain significance, to improve the patient's quality of life.Methods:According to epidemiological analysis of requirements, in November 2006-2009year in November in Qingdao five hospitals oncology 464 cases of lung cancer patients receiving chemotherapy were retrospectively analyzed the use of chemotherapy drugs paclitaxel, docetaxel, gemcitabine, vinorelbine, etoposide, and cis-platinum. And have all completed four cycles of chemotherapy. Evaluation of anti-cancer drugs under the WHO criteria Evaluation of 464 cases of patients. Followed by treatment or treatment of bone marrow suppression that followed the extent of reaction divided into two groups,0-Ⅱ°of "A" group,Ⅲ°and above for the "B" group. Application of medical statistics in two categories Logistic regression equations of the general factors and treatment of patients with factors such as bone marrow suppression may occur related factors were analyzed. Since the variable factors were age, sex, KPS score, tumor type, bad habits, with or without bone metastases, whether platinum-containing agents, pre-treatment white blood cell count, pre-treatment red blood cell count, pre-treatment hemoglobin, pre-treatmentplatelet count, platinum agent dosage, how many times treatment, the number of days, onset time and the availability of underlying diseases, etc.; in which gender, tumor type, with or without bad habits, with or without bone metastases, whether platinum-containing agents as well as theno underlying diseases, the six factors were independent variables in the classification variables. Statistical software using SPSS11.5 software, Logistic analysis process used in the tick variable selection methods are:the use of likelihood ratio statistic of the backward method (Backward:LR), so when P≤0.1 when we consider that the factors are a statistically different.Result:All the patients according to their tumor type and stage given different chemotherapy regimens, the efficacy of treatment for all patients to assess efficiency (RR) up to 40.4%, of which 36.4% of adenocarcinoma, squamous cell carcinoma 45.8%, small cell carcinoma 39.0%, more than 88% of patients for therapeutic purposes.464 cases of patient information and data:age, sex, KPS score, tumor type, bad habits, with or without bone metastases, whether platinum-containing agents, pre-treatment white blood cell count, pre-treatment red blood cell count, pre-treatment hemoglobin, platelet count before treatment, platinum agent dosage, how many times treatment, the number of days, onset time and the availability of underlying disease and so on, have been collated to be used after SPSS 11.5 statistical analysis software to be X3, X7, X8, X10, X11, X12 and X16 there are statistically significant. They are KPS score (P<0.01), amount of platinum agents (P<0.01), the number of treatment days (P<0.05), pre-treatment red blood cell count (P< 0.01), pre-treatment white blood cell count (P< 0.05), pre-treatment hemoglobin (P<0.05) and with or without bone metastases (P＜0.01).Conclusion:Through analysis, confirm KPS score, platinum agents use, pre-treatment red blood cell count, pre-treatment white blood cell count, hemoglobin and the with or without bone metastases, for lung cancer chemotherapy-induced bone marrow suppression response factor.